Developmental Trends in Targeted Radionuclide Therapy of Neuroendocrine Tumors

被引：0

作者：

Mahdavi, Mohamadreza Nouri ^{[1
]}

机构：

[1] Uppsala Univ, Dept Biomed Radiat Sci, Rudbeck Lab, Uppsala, Sweden

来源：

IRANIAN JOURNAL OF NUCLEAR MEDICINE | 2009年 / 17卷 / 02期

关键词：

Neuroendocrine tumors; Somatostatin receptors; Targeted therapy;

D O I：

暂无

中图分类号：

R8 [特种医学]; R445 [影像诊断学];

学科分类号：

1002 ; 100207 ; 1009 ;

摘要：

Neuroendocrine tumors (NETs) constitute a heterogeneous group of neoplasms including carcinoids, pancreatic neuroendocrine tumors, pituitary tumors, medullary thyroid carcinoma and phaeochromocytomas. The symptoms and the outcome of NETs differ considerably between patients depending on several factors. By labelling tracers with a radioisotope, the tracer acts as a carrier to deliver the radioactivity to tissues expressing somatostatin receptors (SSTRs) and may be used for diagnosis and treatment. Several factors influence the selection of an appropriate therapeutic radioisotope. A longer physical half-life and low dose rate may be more effective for relatively indolent malignancies such as NETs. Radiolabelled targeted therapy is a fairly recent and promising modality for the management of patients with inoperable or disseminated NETs when conventional therapies fail.

引用

页码：6 / 11

页数：6

共 50 条

[31] Efficiency and Safety of Targeted Alpha Therapy in Metastatic Neuroendocrine Tumors A Meta-analysis [J].

Lee, Dong Yun ;

Kim, Yong-il .

CLINICAL NUCLEAR MEDICINE, 2025, 50 (01) :e1-e6

[32] 225Ac-MACROPATATE: A Novel a-Particle Peptide Receptor Radionuclide Therapy for Neuroendocrine Tumors [J].

King, Paden ;

Gutsche, Nicholas T. ;

Raju, Natarajan ;

Fayn, Stanley ;

Baidoo, Kwamena E. ;

Bell, Meghan M. ;

Olkowski, Colleen S. ;

Swenson, Rolf E. ;

Lin, Frank I. ;

Sadowski, Samira M. ;

Adler, Stephen S. ;

Thiele, Nikki A. ;

Wilson, Justin J. ;

Choyke, Peter L. ;

Escorcia, Freddy E. .

JOURNAL OF NUCLEAR MEDICINE, 2023, 64 (04) :549-554

[33] Factors Contributing to Tumor Shrinkage after Peptide Receptor Radionuclide Therapy in Patients with Unresectable Neuroendocrine Tumors [J].

Hasegawa, Sho ;

Kobayashi, Noritoshi ;

Wild, Damian ;

Kaul, Fesupplix ;

Okubo, Naoki ;

Suzuki, Akihiro ;

Kurita, Yusuke ;

Takano, Shoko ;

Nakajima, Atsushi ;

Ichikawa, Yasushi .

CANCERS, 2022, 14 (14)

[34] New horizons for targeted treatment of neuroendocrine tumors [J].

Mangano, Alberto ;

Lianos, Georgios D. ;

Roukos, Dimitrios H. ;

Mason, Sam E. ;

Kim, Hoon Yub ;

Dionigi, Gianlorenzo .

FUTURE ONCOLOGY, 2016, 12 (08) :1059-1065

[35] Medical therapy of neuroendocrine tumors [J].

Pavel, M. .

ONKOLOGE, 2011, 17 (07) :592-+

[36] Resistance to targeted treatment of gastroenteropancreatic neuroendocrine tumors [J].

Beyens, Matthias ;

Vandamme, Timon ;

Peeters, Marc ;

Van Camp, Guy ;

Op de Beeck, Ken .

[37] Y90 selective internal radiation therapy and peptide receptor radionuclide therapy for the treatment of metastatic neuroendocrine tumors: combination or not? [J].

Yilmaz, Ebru ;

Engin, Muege Nur ;

Ozkan, Zeynep Gozde ;

Kovan, Bilal ;

Buyukkaya, Fikret ;

Poyanli, Arzu ;

Saglam, Sezer ;

Basaran, Mert ;

Turkmen, Cuneyt .

NUCLEAR MEDICINE COMMUNICATIONS, 2020, 41 (12) :1242-1249

[38] Clinical Advances and Perspectives in Targeted Radionuclide Therapy [J].

Lepareur, Nicolas ;

Ramee, Barthelemy ;

Mougin-Degraef, Marie ;

Bourgeois, Mickael .

PHARMACEUTICS, 2023, 15 (06)

[39] Combination Strategies to Improve Targeted Radionuclide Therapy [J].

Chan, Tiffany G. ;

O'Neill, Edward ;

Habjan, Christine ;

Cornelissen, Bart .

JOURNAL OF NUCLEAR MEDICINE, 2020, 61 (11) :1544-1552

[40] ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: Peptide Receptor Radionuclide Therapy with Radiolabeled Somatostatin Analogs [J].

Kwekkeboom, Dik J. ;

Krenning, Eric P. ;

Lebtahi, Rachida ;

Komminoth, Paul ;

Kos-Kudla, Beata ;

de Herder, Wouter W. ;

Ploeckinger, Ursula .

NEUROENDOCRINOLOGY, 2009, 90 (02) :220-226

← 1 2 3 4 5 →